Myriad Genetics, Inc. (MYGN)
USD 7.29
(-0.07%)
USD 7.29
(-0.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 312.9 Million USD | -11.33% |
| 2021 | 352.9 Million USD | -34.38% |
| 2020 | 537.8 Million USD | 13.51% |
| 2019 | 473.8 Million USD | 0.0% |
| 2018 | 473.8 Million USD | 126.48% |
| 2017 | 209.2 Million USD | -53.16% |
| 2016 | 446.6 Million USD | 237.31% |
| 2015 | 132.4 Million USD | 27.19% |
| 2014 | 104.1 Million USD | -0.68% |
| 2013 | 104.81 Million USD | 39.33% |
| 2012 | 75.22 Million USD | 36.84% |
| 2011 | 54.97 Million USD | 24.84% |
| 2010 | 44.03 Million USD | 21.42% |
| 2009 | 36.26 Million USD | 12.62% |
| 2008 | 32.2 Million USD | -56.3% |
| 2007 | 73.68 Million USD | 132.42% |
| 2006 | 31.7 Million USD | 18.2% |
| 2005 | 26.82 Million USD | 15.19% |
| 2004 | 23.28 Million USD | 54.41% |
| 2003 | 15.08 Million USD | -22.01% |
| 2002 | 19.33 Million USD | -32.2% |
| 2001 | 28.52 Million USD | -12.47% |
| 2000 | 32.58 Million USD | 13.66% |
| 1999 | 28.66 Million USD | 430.9% |
| 1998 | 5.4 Million USD | -45.45% |
| 1997 | 9.9 Million USD | 0.0% |
| 1996 | 9.9 Million USD | 5.32% |
| 1995 | 9.4 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 465.7 Million USD | 3.03% |
| 2023 Q1 | 334.1 Million USD | 6.78% |
| 2023 Q2 | 452 Million USD | 35.29% |
| 2022 FY | 312.9 Million USD | -11.33% |
| 2022 Q4 | 312.9 Million USD | 5.92% |
| 2022 Q3 | 295.4 Million USD | 12.4% |
| 2022 Q2 | 262.8 Million USD | -13.92% |
| 2022 Q1 | 305.3 Million USD | -13.49% |
| 2021 FY | 352.9 Million USD | -34.38% |
| 2021 Q1 | 461.7 Million USD | -14.33% |
| 2021 Q2 | 457.9 Million USD | -0.82% |
| 2021 Q3 | 367.4 Million USD | -19.76% |
| 2021 Q4 | 352.9 Million USD | -3.95% |
| 2020 FY | 537.8 Million USD | 13.51% |
| 2020 Q1 | 479.5 Million USD | -4.29% |
| 2020 Q3 | 535.2 Million USD | 10.03% |
| 2020 Q2 | 486.4 Million USD | 1.44% |
| 2020 Q4 | 538.9 Million USD | 0.69% |
| 2019 FY | 473.8 Million USD | 0.0% |
| 2019 Q1 | 475.6 Million USD | -3.43% |
| 2019 Q2 | 473.8 Million USD | -0.38% |
| 2019 Q3 | 516.7 Million USD | 9.05% |
| 2019 Q4 | 501 Million USD | -3.04% |
| 2018 FY | 473.8 Million USD | 126.48% |
| 2018 Q3 | 471.4 Million USD | 125.33% |
| 2018 Q4 | 492.5 Million USD | 4.48% |
| 2018 Q1 | 270.1 Million USD | -14.06% |
| 2018 Q2 | 209.2 Million USD | -22.55% |
| 2017 Q1 | 519.9 Million USD | -4.32% |
| 2017 FY | 209.2 Million USD | -53.16% |
| 2017 Q2 | 446.6 Million USD | -14.1% |
| 2017 Q3 | 357.7 Million USD | -19.91% |
| 2017 Q4 | 314.3 Million USD | -12.13% |
| 2016 Q4 | 543.4 Million USD | 1.46% |
| 2016 FY | 446.6 Million USD | 237.31% |
| 2016 Q2 | 132.4 Million USD | 35.1% |
| 2016 Q1 | 98 Million USD | -2.87% |
| 2016 Q3 | 535.6 Million USD | 304.53% |
| 2015 Q3 | 99.9 Million USD | -4.03% |
| 2015 FY | 132.4 Million USD | 27.19% |
| 2015 Q1 | 110.15 Million USD | 25.72% |
| 2015 Q2 | 104.1 Million USD | -5.49% |
| 2015 Q4 | 100.9 Million USD | 1.0% |
| 2014 Q3 | 96.85 Million USD | -7.59% |
| 2014 Q1 | 94.18 Million USD | 16.69% |
| 2014 Q2 | 104.81 Million USD | 11.29% |
| 2014 Q4 | 87.61 Million USD | -9.54% |
| 2014 FY | 104.1 Million USD | -0.68% |
| 2013 Q2 | 75.22 Million USD | 17.36% |
| 2013 FY | 104.81 Million USD | 39.33% |
| 2013 Q3 | 91.38 Million USD | 21.48% |
| 2013 Q4 | 80.71 Million USD | -11.68% |
| 2013 Q1 | 64.09 Million USD | 15.23% |
| 2012 Q4 | 55.62 Million USD | -17.58% |
| 2012 Q1 | 47.06 Million USD | 5.77% |
| 2012 Q2 | 54.97 Million USD | 16.82% |
| 2012 Q3 | 67.49 Million USD | 22.77% |
| 2012 FY | 75.22 Million USD | 36.84% |
| 2011 Q4 | 44.49 Million USD | 9.21% |
| 2011 Q1 | 32.82 Million USD | 0.96% |
| 2011 Q3 | 40.74 Million USD | -7.48% |
| 2011 Q2 | 44.03 Million USD | 34.17% |
| 2011 FY | 54.97 Million USD | 24.84% |
| 2010 Q1 | 22.21 Million USD | -2.18% |
| 2010 FY | 44.03 Million USD | 21.42% |
| 2010 Q4 | 32.5 Million USD | -18.18% |
| 2010 Q3 | 39.73 Million USD | 9.55% |
| 2010 Q2 | 36.26 Million USD | 63.24% |
| 2009 Q3 | 20.99 Million USD | -34.81% |
| 2009 Q4 | 22.71 Million USD | 8.18% |
| 2009 Q1 | 36.5 Million USD | -32.18% |
| 2009 Q2 | 32.2 Million USD | -11.78% |
| 2009 FY | 36.26 Million USD | 12.62% |
| 2008 Q3 | 54.18 Million USD | -26.47% |
| 2008 Q4 | 53.82 Million USD | -0.67% |
| 2008 Q2 | 73.68 Million USD | 95.66% |
| 2008 Q1 | 37.66 Million USD | 7.94% |
| 2008 FY | 32.2 Million USD | -56.3% |
| 2007 Q4 | 34.89 Million USD | 10.33% |
| 2007 FY | 73.68 Million USD | 132.42% |
| 2007 Q1 | 22.96 Million USD | -13.27% |
| 2007 Q3 | 31.62 Million USD | -0.26% |
| 2007 Q2 | 31.7 Million USD | 38.08% |
| 2006 Q2 | 26.82 Million USD | 24.22% |
| 2006 Q4 | 26.47 Million USD | 15.36% |
| 2006 Q1 | 21.59 Million USD | -8.44% |
| 2006 FY | 31.7 Million USD | 18.2% |
| 2006 Q3 | 22.94 Million USD | -14.45% |
| 2005 Q3 | 22.34 Million USD | -4.03% |
| 2005 Q2 | 23.28 Million USD | 40.79% |
| 2005 Q1 | 16.53 Million USD | -4.72% |
| 2005 FY | 26.82 Million USD | 15.19% |
| 2005 Q4 | 23.58 Million USD | 5.53% |
| 2004 Q4 | 17.35 Million USD | 25.24% |
| 2004 Q3 | 13.86 Million USD | -8.08% |
| 2004 Q2 | 15.08 Million USD | 1.62% |
| 2004 FY | 23.28 Million USD | 54.41% |
| 2004 Q1 | 14.84 Million USD | 15.13% |
| 2003 Q3 | 12.21 Million USD | -36.86% |
| 2003 Q4 | 12.89 Million USD | 5.57% |
| 2003 Q2 | 19.33 Million USD | 49.68% |
| 2003 Q1 | 12.91 Million USD | -40.38% |
| 2003 FY | 15.08 Million USD | -22.01% |
| 2002 Q3 | 16.08 Million USD | -43.6% |
| 2002 Q1 | 18.93 Million USD | -7.0% |
| 2002 FY | 19.33 Million USD | -32.2% |
| 2002 Q4 | 21.66 Million USD | 34.72% |
| 2002 Q2 | 28.52 Million USD | 50.65% |
| 2001 FY | 28.52 Million USD | -12.47% |
| 2001 Q4 | 20.35 Million USD | -7.35% |
| 2001 Q2 | 32.58 Million USD | 41.58% |
| 2001 Q3 | 21.97 Million USD | -32.57% |
| 2001 Q1 | 23.01 Million USD | 6.04% |
| 2000 Q2 | 28.66 Million USD | 26.76% |
| 2000 Q4 | 21.7 Million USD | -9.68% |
| 2000 Q3 | 24.02 Million USD | -16.18% |
| 2000 Q1 | 22.61 Million USD | 22.92% |
| 2000 FY | 32.58 Million USD | 13.66% |
| 1999 FY | 28.66 Million USD | 430.9% |
| 1999 Q1 | 5.8 Million USD | -12.12% |
| 1999 Q4 | 18.4 Million USD | 28.67% |
| 1999 Q3 | 14.3 Million USD | 164.81% |
| 1999 Q2 | 5.4 Million USD | -6.9% |
| 1998 Q1 | 9.2 Million USD | -6.12% |
| 1998 Q3 | 7.8 Million USD | -21.21% |
| 1998 FY | 5.4 Million USD | -45.45% |
| 1998 Q2 | 9.9 Million USD | 7.61% |
| 1998 Q4 | 6.6 Million USD | -15.38% |
| 1997 Q1 | 8.7 Million USD | -9.38% |
| 1997 Q4 | 9.8 Million USD | -2.0% |
| 1997 Q3 | 10 Million USD | 1.01% |
| 1997 Q2 | 9.9 Million USD | 13.79% |
| 1997 FY | 9.9 Million USD | 0.0% |
| 1996 Q2 | 9.4 Million USD | 1.08% |
| 1996 Q3 | 10 Million USD | 6.38% |
| 1996 Q4 | 9.6 Million USD | -4.0% |
| 1996 Q1 | 9.3 Million USD | 75.47% |
| 1996 FY | 9.9 Million USD | 5.32% |
| 1995 Q4 | 5.3 Million USD | 0.0% |
| 1995 FY | 9.4 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -677.855% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -3464.12% |
| Aspira Women's Health Inc. | 8.62 Million USD | -3526.985% |
| Biodesix, Inc. | 94.51 Million USD | -231.055% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -17862.721% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -9195.08% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -9195.08% |
| Bionano Genomics, Inc. | 118.24 Million USD | -164.616% |
| CareDx, Inc | 223.28 Million USD | -40.134% |
| Check-Cap Ltd. | 1.33 Million USD | -23426.316% |
| Castle Biosciences, Inc. | 86.54 Million USD | -261.559% |
| DarioHealth Corp. | 38.24 Million USD | -718.146% |
| Exact Sciences Corporation | 3.32 Billion USD | 90.592% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -123.783% |
| Guardant Health, Inc. | 1.62 Billion USD | 80.777% |
| ICON Public Limited Company | 7.74 Billion USD | 95.962% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 82.376% |
| Illumina, Inc. | 4.36 Billion USD | 92.833% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -5491.822% |
| iSpecimen Inc. | 6.07 Million USD | -5048.024% |
| Standard BioTools Inc. | 159.86 Million USD | -95.728% |
| MDxHealth SA | 121.92 Million USD | -156.635% |
| 23andMe Holding Co. | 206.64 Million USD | -51.418% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 71.5% |
| Mainz Biomed B.V. | 12.15 Million USD | -2473.233% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -28471.246% |
| NeoGenomics, Inc. | 739.69 Million USD | 57.699% |
| Neogen Corporation | 1.44 Billion USD | 78.271% |
| Inotiv, Inc. | 588.04 Million USD | 46.789% |
| Natera, Inc. | 691.79 Million USD | 54.77% |
| OpGen, Inc. | 13.44 Million USD | -2227.457% |
| OPKO Health, Inc. | 622.47 Million USD | 49.733% |
| Psychemedics Corporation | 6.59 Million USD | -4642.346% |
| Prenetics Global Limited | 44.01 Million USD | -610.922% |
| Prenetics Global Limited | 44.01 Million USD | -610.922% |
| Precipio, Inc. | 3.67 Million USD | -8421.242% |
| Personalis, Inc. | 95.65 Million USD | -227.103% |
| RadNet, Inc. | 2.07 Billion USD | 84.908% |
| Sera Prognostics, Inc. | 25.28 Million USD | -1137.59% |
| Sotera Health Company | 2.68 Billion USD | 88.354% |
| Neuronetics, Inc. | 81.64 Million USD | -283.263% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -1343.599% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -1343.599% |
| Trinity Biotech plc | 83.38 Million USD | -275.252% |
| T2 Biosystems, Inc. | 62.83 Million USD | -397.987% |
| Twist Bioscience Corporation | 152.97 Million USD | -104.549% |
| Exagen Inc. | 34.25 Million USD | -813.577% |